کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5882274 | 1149461 | 2015 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study](/preview/png/5882274.png)
چکیده انگلیسی
These findings support those from recent studies that RAS and BRAF mutations are associated with poor outcome in patients receiving an epidermal growth factor receptor-targeted monoclonal antibody in combination with oxaliplatin-based chemotherapy. Furthermore, mutation testing should not only include RAS codons 12 and 13 but should also be extended to the entire coding regions.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Colorectal Cancer - Volume 14, Issue 2, June 2015, Pages 91-98
Journal: Clinical Colorectal Cancer - Volume 14, Issue 2, June 2015, Pages 91-98
نویسندگان
Klaus Kaczirek, Tudor E. Ciuleanu, Damir Vrbanec, Erika Marton, Diethelm Messinger, Bernadette Liegl-Atzwanger, Fritz Wrba, Regina Knittelfelder, Elisabeth Lindner, Christoph C. Zielinski, Berthold Streubel, Thomas Brodowicz,